@Article{Bińkowska2022,
journal="Menopause Review/Przegląd Menopauzalny",
issn="1643-8876",
volume="21",
number="3",
year="2022",
title="Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings",
abstract="Two important studies evaluating the safety profile of oral estrogen-progestogen hormonal therapies conducted in standard clinical practice with respect to the venous system were recently published.   A large prospective controlled cohort study (PRO-E2) based on the non-inferiority design has shown that the relative risk of developing venous thrombosis (VTE) in women using combined oral hormonal contraceptives (COHC) containing 17-estradiol (1.5 mg) and nomegestrol acetate (2.5 mg) (E2/NOMAC) was not statistically different from that in users of COHC containing ethinylestradiol and levonorgestrel (EE/LNG).  The aim of the recently presented study was to compare the risk of VTE in patients treated with a product for oral continuous combined menopausal hormone therapy containing 1 mg of 17ß-estradiol and 100 mg of micronized progesterone (1 mgE2/100 mgP4) with patients taking conjugated equine estrogens and medroxyprogesterone acetate (CEE/MPA). The study was based on an analysis of records retrieved from a US health insurance database, and was therefore concerned the real-life clinical practice. The hazard ratio of VTE when comparing 1 mgE2/100 mgP4 with CEE/MPA was 0.70 (95% CI: 0.53–0.92). The difference was found to be statistically significant (p < 0.05).   The rewieved studies provide further evidence that the use of hormones bioidentical with endogenous steroids in oral contraception and menopausal hormone therapy creates an opportunity to combine high efficacy with a favorable safety profile.",
author="Bińkowska, Małgorzata
and Jakimiuk, Artur
and Paszkowski, Tomasz
and Pawelczyk, Leszek
and Skrzypulec-Plinta, Violetta",
pages="197--199",
doi="10.5114/pm.2022.119861",
url="http://dx.doi.org/10.5114/pm.2022.119861"
}